Johnson & Johnson jab may cause unusual blood clotting

According to the EU agency, over 7 million people received the product of the Johnson & Johnson pharma company


Anadolu Agency April 22, 2021

BRUSSELS:

The European Medicine Agency (EMA) confirmed on Tuesday that there could be a link between Johnson & Johnson vaccines and very rare cases of blood clots.

“A warning about unusual blood clots with low blood platelets should be added to the product information for Covid-19 Vaccine Janssen,” the EU regulator announced in a statement following the investigation of its safety committee.

But the EMA upheld its recommendation to use the jabs and confirmed that its benefits outweighed possible risks.

Autoimmune-disease drugs may reduce vaccine response

The investigation also concluded that “blood clots occurred mostly at unusual sites such as in veins in the brain (cerebral venous sinus thrombosis, CVST) and the abdomen (splanchnic vein thrombosis) and in arteries, together with low levels of blood platelets and sometimes bleeding.”

According to the EU agency, over 7 million people received the product of the Johnson & Johnson pharma company and it caused serious blood clotting in eight cases.

The cases were very similar to the side effects of AstraZeneca’s coronavirus disease (Covid-19) vaccines.

Twitter becomes platform of hope amid the despair of India's Covid crisis

In March, several European countries – including Sweden, Germany, France, Italy, Ireland, the Netherlands, Denmark, and Norway – suspended the use of AstraZeneca jabs for a while after blood clots were reported in some vaccinated people.

The EMA’s investigation also concluded on April 7 that there could be a possible link between AstraZeneca vaccines and very rare cases of blood clots.

Similarly, the EU regulator upheld its recommendation on using the jabs since its benefits outweighed the risks.

Our Publications

COMMENTS

Replying to X

Comments are moderated and generally will be posted if they are on-topic and not abusive.

For more information, please see our Comments FAQ